SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical ...
SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a ...
Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...
Myriad Genetics, Inc. MYGN recently published results from a meta-analysis in the Journal of Clinical Psychopharmacology, stating the superiority of the company’s GeneSight Psychotropic test over ...
SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of ...
Hosted on MSN
GeneSight test-guided treatment leads to faster remission and response in patients with depression
Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in Mental Health Care (PRIME) study showed that ...
Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies that included 3,532 ...
The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the ...
*Note to reader: This article discusses suicidal ideation. If you or someone you know needs support now, call or text 988 for the suicide and crisis lifeline. Imagine going through your days not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback